All In Biotech

Drug Trial Radar · NCT05267470

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Bemarituzumab Monotherapy and Combination With Other Anti-Cancer Therapy in Subjects With Squamous-Cell Non-Small-Cell Lung Cancer (FORTITUDE-201)

Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

74

Actual

Start

Mar 29, 2022

Primary completion

May 28, 2024

Study completion May 28, 2024

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety and tolerability of bemarituzumab monotherapy and combination with other anti-cancer therapies, and to determine the recommended phase 3 dose of bemarituzumab in combination with other anti-cancer therapies.

Conditions

  • Squamous-Cell Non-Small-Cell Lung Cancer

Interventions

  • BemarituzumabDrug

    Intravenous (IV) infusion

  • DocetaxelDrug

    IV infusion

  • PembrolizumabDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • Nab-paclitaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced a Dose Limiting Toxicity (DLT): Parts 1 and 4Time frame: Day 1 to Day 21 of Cycle 1 (each cycle was 21 days)
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks.

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • University of California Irvine

    Orange, California

  • Morristown Medical Center

    Morristown, New Jersey

  • Montefiore Einstein Center for Cancer Care

    The Bronx, New York

  • University of Pittsburgh, Cancer Institute

    Pittsburgh, Pennsylvania

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Jessa Ziekenhuis - Campus Virga Jesse

    Hasselt, Belgium

  • Institut Bergonie

    Bordeaux, France

  • CHU de Lyon - Hopital Louis Pradel

    Bron, France

  • Hôpital Tenon

    Paris, France

  • Centre Hospitalier Universitaire de Poitiers - Hopital la Miletrie

    Poitiers, France

  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou

    Rennes, France

  • Institut Gustave Roussy

    Villejuif, France

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan

  • Shizuoka Cancer Center

    Sunto-gun, Shizuoka, Japan

  • Wakayama Medical University Hospital

    Wakayama, Wakayama, Japan

  • Przychodnia Lekarska Komed Roman Karaszewski

    Konin, Poland

  • Pratia Mcm Krakow

    Krakow, Poland

  • Krakowskie Centrum Medyczne Sp zoo

    Krakow, Poland

  • Instytut Centrum Zdrowia Matki Polki

    Lodz, Poland

  • Instytut Genetyki i Immunologii GENIM Spzoo

    Lublin, Poland

  • Centrum Medyczne Hope Clinic Sebastian Szklener

    Lublin, Poland

  • Mazowieckie centrum leczenia

    Otwock, Poland

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, Andalusia, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Andalusia, Spain

  • Hospital Universitari Vall d Hebron

    Barcelona, Catalonia, Spain

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, Catalonia, Spain

  • Institut Catala d Oncologia Hospitalet. Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Catalonia, Spain

  • Complexo Hospitalario Universitario A Coruña Hospital Teresa Herrera

    A Coruña, Galicia, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Madrid, Spain

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.